Early data from a Phase 2 clinical trial show a combination of immunotherapy medications can activate a robust immune ...

More than half of melanoma patients whose cancer initially responds to immunotherapy will eventually see their disease return ...

University of Cincinnati reported positive Phase 2 melanoma trial results, with a third of patients responding to a combined ...

NEO-CYT is a randomized, multi-centre trial of neoadjuvant MDNA11 (before curative intent surgery) sponsored by the Fondazione Melanoma Onlus, ...

New research from Moffitt Cancer Center shows that RAS(ON) multi-selective inhibition can directly block tumor growth and ...

The latest update is out from Scancell Holdings ( (GB:SCLP) ).

Researchers review melanoma subtypes, focusing on therapeutic advances in metastatic ocular melanoma, including TILs, ImmTACs, and targeted therapies.

Immune therapy is generally safer than chemotherapy, allowing more patients with melanoma and other conditions like heart or lung issues receive treatment. Immune therapy is generally better tolerated ...

Neuroblastoma RAS viral oncogene homolog (NRAS)-mutant melanoma is an aggressive form of skin cancer that develops because of ...

The novel Tumor Profiler (TuPro) project, which analyzed melanoma samples using nine independent technologies, demonstrated feasibility in guiding treatment decisions. Molecular tumor board ...

The mutual goal of the National Comprehensive Cancer Network (NCCN) and the American Cancer Society partnership is to provide patients and the general public with state of the art cancer treatment ...

Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological ...